My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Bayer to acquire Monsanto in all cash transaction

Bayer to acquire Monsanto in all cash transaction

Sep 14,2016

Monsanto India announced that Bayer and Monsanto signed definitive agreement under which Bayer will acquire Monsanto for USD 128 per share in an all cash transaction.

Powered by Capital Market - Live News

Sasken Technologies declines after weak Q1 earnings
Jul 19,2017

The result was announced after market hours yesterday, 18 July 2017.

Meanwhile, the S&P BSE Sensex was up 130.09 points, or 0.41% at 31,841.08. The S&P BSE Small-Cap index was up 127.82 points, or 0.81% at 15,945.42.

On the BSE, 11,000 shares were traded on the counter so far as against the average daily volumes of 29,023 shares in the past one quarter. The stock had hit a high of Rs 507.75 and a low of Rs 474.95 so far during the day. The stock had hit a 52-week high of Rs 578.90 on 13 July 2017 and a 52-week low of Rs 326.80 on 30 September 2016.

The stock had outperformed the market over the past one month till 18 July 2017, advancing 24.35% compared with the Sensexs 2.11% rise. The scrip had also outperformed the market over the past one quarter gaining 26.34% as against the Sensexs 8.16% rise. The scrip had also outperformed the market over the past one year advancing 46.47% as against the Sensexs 14.29% rise.

The small-cap company has equity capital of Rs 17.72 crore. Face value per share is Rs 10.

Rajiv C Mody, Chairman, Managing Director & CEO, Sasken Technologies said that in Q1 June 2017, the companys revenues have remained flat. Sasken Technologies is confident that its engineering DNA will help it to tap the opportunities in the segments it operate in. The company is encouraged by the market traction in both of its product engineering and digital IT services as investments continue to fuel the growth of the digital enterprise, Rajiv said.

Sasken Technologies is engaged in software development. It provides engineering research and development (ER&D), and productized information technology (IT) services to customers in the communications and devices, retail, insurance and independent software sectors.

Powered by Capital Market - Live News

Ingersoll-Rand (India) to hold board meeting
Jul 19,2017

Ingersoll-Rand (India) will hold a meeting of the Board of Directors of the Company on 2 August 2017, to take on record the Unaudited Financial Results of the Company for the quarter ended 30 June 2017.

Powered by Capital Market - Live News

Redington India to hold board meeting
Jul 19,2017

Redington India will hold a meeting of the Board of Directors of the Company on 27 July 2017, to consider, unaudited financial results for the quarter ended 30th June 2017.

Powered by Capital Market - Live News

PVR to hold board meeting
Jul 19,2017

PVR will hold a meeting of the Board of Directors of the Company on 26 July 2017, to consider and approve un-audited Standalone and Consolidated Financial Results of the Company for the first quarter ended on 30th June 2017.

Powered by Capital Market - Live News

MoU Signed Between Department Of Defence Production And GRSE
Jul 19,2017

A Memorandum of Understanding (MoU) was signed between Secretary (Defence Production) Shri Ashok Kumar Gupta on behalf of the Ministry of Defence and Chairman and Managing Director (CMD), Garden Reach Shipbuilders & Engineers Limited (GRSE) Rear Adm (Retd) VK Saxena. The MoU details the targets and achievements expected on various MoU performance indicators of the company during 2017-18.

The company has targeted to achieve a turnover of ₹ 1350 crore which is about 40 percent more than actual achievements of last financial year (2016-17).

During the current year, the company planned to spend ₹ 50 crore as CAPEX for further strengthening the infrastructure facilities including improving the design capabilities for construction of P-17A ships.

As part of Make in India initiative of the Government, GRSE has set a target to develop Indigenous Capability and Infrastructure for Assembly, Test & Trial of Marine Diesel Engines, at its Engine Plant at Ranchi, during the current financial year.

Powered by Capital Market - Live News

Majesco gains after securing contract
Jul 19,2017

The announcement was made after market hours yesterday, 18 July 2017.

Meanwhile, the S&P BSE Sensex was up 123.40 points or 0.39% at 31,834.39. The S&P BSE Small-Cap index rose 123.24 points or 0.78% at 15,940.84.

On the BSE, 46,000 shares were traded on the counter so far as against the average daily volumes of 23,044 shares in the past one quarter. The stock had hit a high of Rs 378.95 and a low of Rs 366 so far during the day. The stock had hit a 52-week high of Rs 575 on 25 July 2016 and a 52-week low of Rs 300 on 10 July 2017.

The stock had outperformed the market over the past one month till 18 July 2017, advancing 12.12% compared with the Sensexs 2.11% rise. The stock had, however, underperformed the market over the past one quarter, declining 3.32% as against the Sensexs 8.16% rise. The scrip had also underperformed the market over the past one year, sliding 27.77% as against the Sensexs 14.29% rise.

The small-cap company has equity capital of Rs 11.73 crore. Face value per share is Rs 5.

Majesco said that Majesco, USA, (Majesco) the insurance arm and a subsidiary of Majesco announced about the selection of the Majesco CloudInsurer platform by a leading provider of financial protection benefits globally, to transform their collections operation across multiple geographies.

In the first phase, they will implement Majesco CloudInsurer to modernize their collection operations in one country to be followed by other Latin America countries and additional territories in the Middle East and Asia.

Majescos consolidated net profit fell 49.9% to Rs 2.54 crore on 7.16% decrease in net sales to Rs 187.78 crore in Q4 March 2017 over Q3 December 2016.

Majesco enables insurance business transformation for insurance customers worldwide by providing solutions which include software, consulting and services.

Powered by Capital Market - Live News

Power Grid lights up after subsidiary commissions project
Jul 19,2017

The announcement was made after market hours yesterday, 18 July 2017.

Meanwhile, the S&P BSE Sensex was up 109.15 points or 0.34% at 31,820.14.

On the BSE, 6,248 shares were traded in the counter so far as against average daily volume of 5.22 lakh shares in the past one quarter.

The stock had hit a high of Rs 216.90 and a low of Rs 215.50 so far during the day. The stock had hit a record high of Rs 220 yesterday, 18 July 2017. The stock had hit a 52-week low of Rs 162.20 on 21 July 2016.

The stock had outperformed the market over the past one month till 18 July 2017, gaining 2.82% compared with Sensexs 2.11% gains. The scrip had, however, underperformed the market in past one quarter, gaining 6.45% as against Sensexs 8.16% rise. The scrip had, however, outperformed the market in past one year, gaining 31.86% as against Sensexs 14.29% rise.

The large-cap power distribution company has equity capital of Rs 5231.59 crore. Face value per share is Rs 10.

Power Grid Corporation of India said that POWERGRID Kala Amb Transmission, wholly owned subsidiary of the company secured though Tariff Based Competitive Bidding (TBCB), has declared commissioning of its project on 12 July 2017.

Power Grid Corporation of Indias net profit rose 22.2% to Rs 1916.36 crore on 16.9% rise in net sales to Rs 6712.04 crore in Q4 March 2017 over Q4 March 2016.

The Government of India holds 57.9% stake in the firm as at 30 June 2017.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals enters into exclusive agreement with Cyndea Pharma
Jul 19,2017

Glenmark Pharmaceuticals has entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S.L., granting exclusive rights to use their technology for developinggeneric, soft-gelatin capsule formulations of certain pharmaceutical products.

Under this agreement, Glenmark receives exclusive rights to the United States and Canada markets for these soft-gelatin formulations in exchange for sharing development costs and profits from future sales. In addition, the agreement provides for the companies to add furthersoft-gelatin product candidates for development and commercialization, as new branded, softgelatin, capsule-based drug products become available in the marketplace.

Powered by Capital Market - Live News

Construction of VIP Terminal at Jaipur Airport
Jul 19,2017

The Airports Authority of India (AAI) has received a request from the state Government of Rajasthan for construction of VVIP Terminal at Jaipur Airport. AAI has already offered 2.5 acres of land to the Govt. of Rajasthan for this purpose.

Powered by Capital Market - Live News

Shares of Steel Exchange India get listed on NSE
Jul 19,2017

Steel Exchange India announced that the existing equity shares of the Company are admitted to listing at National Stock Exchange of India (NSE) w.e.f. 20 July 2017 under symbol STEELXIND

Powered by Capital Market - Live News

National Bamboo Mission renamed as National Agro-Forestry & Bamboo Mission (NABM)
Jul 19,2017

National Bamboo Mission renamed as National Agro-Forestry & Bamboo Mission (NABM) is being implemented as per the set objectives and targets of the Mission. As per available reports 3,61,791 ha. area have been covered in forest & non-forest land, 91,715 ha. area taken up for improvement of existing stock for higher productivity (forest & non-forest areas) under the Mission against targets of 3,62,848 ha., 69,410 ha. respectively.

Under the Mission, 108 nos. of markets (Bamboo wholesale & retail markets near villages, etc.) have been established for providing marketing avenues to bamboo farmers for their raw bamboo as well as finished products. Besides, efforts are being made to popularize bamboo products through participation in domestic/national/international trade fairs.

Under the Mission, Steps have already been taken & are being taken to provide assistance to farmers/bamboo growers for nursery establishment, plantations in non-forest area, imparting training for preparation of nurseries & bamboo plantations, establishing of bamboo markets for farmer products, etc.

Powered by Capital Market - Live News

HUL gains after reporting decent Q1 results
Jul 19,2017

The result was announced after market hours yesterday, 18 July 2017.

Meanwhile, the S&P BSE Sensex was up 103.65 points or 0.33% at 31,814.64.

On the BSE, 21,551 shares were traded on the counter so far as against the average daily volumes of 1.49 lakh shares in the past one quarter. The stock had hit a high of Rs 1,195.10 and a low of Rs 1,153.40 so far during the day.

Hindustan Unilevers (HUL) earnings before interest, tax, depreciation and amortisation (EBITDA) rose by 14%. Profit after tax before exceptional items, PAT (bei), rose 15% to Rs 1292 crore. Under volatile market conditions, the companys domestic consumer business grew at 6% and underlying volume growth remained flat.

During the quarter, trade sentiment remained cautious, particularly in the run up to GST implementation. Despite high promotional intensity, stock pipelines remained low and varied across categories, channels and geographies. In these challenging circumstances the company managed to deliver yet another quarter of resilient and profitable growth.

Harish Manwani, Chairman commented that both growth and margin improvement were delivered through a combination of sustained innovations, a comprehensive savings program and a relentless focus on execution in the market place. The company remains positive on the medium term outlook for the industry and will continue to drive consumer value, which also delivers profitable volume driven growth for the company.

HUL is a leading fast moving consumer goods (FMCG) company.

Powered by Capital Market - Live News

Aurobindo Pharma jumps after FDA approval for generic drug
Jul 19,2017

The announcement was made before market hours today, 19 July 2017.

Meanwhile, the S&P BSE Sensex was up 95.99 points or 0.3% at 31,806.98.

On the BSE, 2.26 lakh shares were traded on the counter so far as against the average daily volumes of 3.53 lakh shares in the past one quarter. The stock had hit a high of Rs 794.50 and a low of Rs 768.55 so far during the day. The stock had hit a record high of Rs 895 on 6 October 2016 and a 52-week low of Rs 504 on 29 May 2017.

The stock had outperformed the market over the past one month till 18 July 2017, advancing 12.43% compared with the Sensexs 2.11% rise. The stock had also outperformed the market over the past one quarter, gaining 10.57% as against the Sensexs 8.16% rise. The scrip had, however, underperformed the market over the past one year, sliding 2.25% as against the Sensexs 14.29% rise.

The large-cap company has equity capital of Rs 58.59 crore. Face value per share is Rs 1.

Aurobindo Pharma received final approval from the US Food & Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800mg. Sevelamer Carbonate tablets, are therapeutic equivalent generic version of Genzymes Renvela tablets. The product is being launched immediately.

Sevelamer Carbonate tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The approved product has an estimated market size of $1.9 billion for the twelve months ending May 2017 according to IMS.

On consolidated basis, net profit of Aurobindo Pharma declined 4% to Rs 532.45 crore on 2.5% decline in net sales to Rs 3582.13 crore in Q4 March 2017 over Q4 March 2016.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients.

Powered by Capital Market - Live News

Aurobindo Pharma receives final approval for Sevelamer Carbonate tablets
Jul 19,2017

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800mg. Sevelamer Carbonate tablets, a therapeutic equivalent generic version of Genzymes Renvelan++ tablets. The product is being launched immediately.

Sevelamer Carbonate tablets is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The approved product has an estimated market size of US$ 1.9 billion forthe twelve months ending May 2017 according to IMS.

Powered by Capital Market - Live News

Zydus Cadila launches Mesalamine Delayed Release Tablets
Jul 19,2017

Zydus Cadila has commercially launched its Mesalamine Delayed Release Tablets USP, 1.2 mg in the US market. Zydus was the first to file an Abbreviated New Drug Application for a generic version of Lialda and is currently the only generic available to patients in the US. The drug is indicated for the treatment of mild to moderate ulcerative colitis.

Powered by Capital Market - Live News